Atossa Therapeutics Inc.
ATOS | NASDAQ
$2.29
+$0.04 (+1.78%)
Sep 22, 2026, 2:15 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Net Income | -34.77M | -25.5M | -30.09M | -26.96M | -20.61M | -17.83M |
Depreciation & Amortization | 16K | 17K | 23K | 8K | 23K | 46.52K |
Stock-Based Compensation | 2.65M | 2.29M | 4.62M | 6.79M | 5.27M | 3.02M |
Other Working Capital | -285K | 575K | 391K | -1.85M | -1.28M | -1.41M |
Other Non-Cash Items | n/a | 1.72M | 2.99M | 3K | n/a | 939.2K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | 2.36M |
Change in Working Capital | 2.35M | 448K | 1.52M | -599K | -1.16M | -111.35K |
Operating Cash Flow | -29.76M | -21.03M | -20.94M | -20.76M | -16.47M | -11.57M |
Capital Expenditures | -23K | -19K | -14K | -27K | -9K | -9.37K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | -4.7M | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -23K | -19K | -14K | -4.73M | -9K | -9.37K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | -1.48M | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | n/a | 43.64M | -13.82K |
Financial Cash Flow | n/a | 3.67M | -1.48M | n/a | 113.3M | 38.55M |
Net Cash Flow | -29.79M | -17.38M | -22.43M | -25.49M | 96.82M | 26.97M |
Free Cash Flow | -29.79M | -21.05M | -20.96M | -20.79M | -16.48M | -11.58M |
Adj. Free Cash Flow | -32.43M | -23.34M | -25.58M | -27.58M | -21.75M | -14.6M |
Maintenance CapEx | -16K | -17K | -14K | -8K | -9K | -9.37K |
Growth CapEx | -7K | -2K | n/a | -19K | n/a | n/a |
Owner Earnings | -29.78M | -21.05M | -20.96M | -20.77M | -16.48M | -11.58M |
Add to Watchlist
Select watchlists to add or remove ATOS